About the Company
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKINDI® SPRINKLE, Biorphen®, and Alaway® Preservative Free, and has six additional products that have been submitted to the FDA.
|Name||Ticker||Market Capitalization (USD M)||Revenue (USD M)||Price/Book||Price/Earning||Net Margin (%)|
|Conversion Labs Inc||CVLB||108548||35213||3.74||42.66||7.33|
|Royalty Pharma plc||RPRX||19327||2239||2.87||15.52||43.40|
|Organon & Co.||OGN||8644||7891||-4.46||4.95||22.06|
|ATAI Life Sciences N.V.||ATAI||2545||20||5.35||-11.65||-932.88|
|Cronos Group Inc||CRON||2114||57||1.33||-14.64||-258.59|
|Usana Health Sciences Inc||USNA||1837||1254||4.18||13.23||11.09|
|Phathom Pharmaceuticals Inc||PHAT||1178||7.99||-7.35||None|
|Fulcrum Therapeutics Inc||FULC||925||15||11.21||-12.53||-481.07|
|Intersect ENT Inc||XENT||899||103||21.80||-13.10||-66.55|
|Phibro Animal Health Corp.||PAHC||888||833||3.68||16.16||6.53|
|Edgewise Therapeutics Inc||EWTX||848||2.87||-31.45||None|
|Pliant Therapeutics Inc||PLRX||657||13||2.69||-7.66||-613.56|
|Cyteir Therapeutics Inc||CYT||637||3.42||-22.04||None|
|Urovant Sciences Ltd||UROV||503||-3.65||-3.08||None|
|Ikena Oncology Inc||IKNA||467||10||2.52||-8.53||-551.28|
|Rain Therapeutics Inc||RAIN||404||413||2.50||-13.27||123.20|
|Provention Bio Inc||PRVB||400||2.68||-3.12||None|
|Verrica Pharmaceuticals Inc||VRCA||316||12||6.41||-8.69||-301.45|
|Terns Pharmaceuticals Inc||TERN||263||1.46||-7.62||None|
|Adicet Bio Inc||ACET||230||9||1.00||-4.09||-603.06|
|Milestone Pharmaceuticals Inc||MIST||222||15||1.25||-7.50||-215.93|
|Kaleido Biosciences Inc||KLDO||222||1||4.94||-2.49||None|
|Kala Pharmaceuticals Inc||KALA||187||11||2.42||-1.48||None|
|Osmotica Pharmaceuticals Plc||OSMT||181||190||2.64||-1.95||-47.85|
|Citius Pharmaceuticals Inc||CTXR||177||2.21||-7.70||None|
|Aquestive Therapeutics Inc||AQST||146||42||-3.02||-2.27||-152.73|
|Eton Pharmaceuticals Inc||ETON||123||15||6.11||-10.06||-74.52|
|Odonate Therapeutics Inc||ODT||117||1.47||-1.00||None|
|Aerpio Pharmaceuticals Inc||ARPO||99||15||2.98||-5.24||-28.77|
|Opiant Pharmaceuticals Inc||OPNT||90||37||2.71||-86.08||-3.06|
|Natural Alternatives Internati||NAII||89||169||1.26||10.07||5.68|
|VYNE Therapeutics Inc||VYNE||72||16||1.08||3.27||-554.66|
|India Globalization Capital In||IGC||67||0||2.39||-7.65||-981.18|
|Acasti Pharma Inc||ACST||42||0||1.81||-2.11||-611.47|
|Assertio Holdings Inc||ASRT||33||117||0.45||-0.58||-38.05|
|Reviva Pharmaceuticals Holding||RVPH||30||1.64||-4.74||None|
|Baudax Bio Inc||BXRX||28||1||-11.98||0.84||None|
|Nabriva Therapeutics Plc||NBRV||28||12||0.83||-0.47||-452.55|
|Bio-Path Holdings Inc||BPTH||28||0||1.29||-2.68||18.96|
|Timber Pharmaceuticals Inc||TMBR||26||0||11.39||0.88||-527.55|
|Trevi Therapeutics Inc||TRVI||26||1.67||-0.74||None|
|Lexaria Bioscience Corp||LEXX||25||1||3.49||-6.45||-445.15|
|Hoth Therapeutics Inc||HOTH||22||1.85||-2.29||None|
|Sonoma Pharmaceuticals Inc.||SNOA||11||17||3.13||-2.04||-31.96|
Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.23 per share a year ago.
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...
Newsflash: Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Analysts Have Been Trimming Their Revenue Forecasts
The analysts covering Eton Pharmaceuticals, Inc. (NASDAQ:ETON) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year.
As with many other companies Eton Pharmaceuticals, Inc. (NASDAQ:ETON) makes use of debt. But should shareholders be worried about its use of debt? Generally speaking, debt only becomes a real ...
Eton Pharmaceuticals is a small specialty pharmaceutical company based just out of Chicago. The company is focused on developing and commercializing pharmaceutical products for rare diseases.
Phenylketonuria Treatment Market 2021–Detailed Analysis of Current and Future Industry Figures till 2027
For instance, BioMarin Pharmaceutical Inc. in 2017, submitted to the U.S. Food and Drug Administration (FDA), a Biologics License Application (BLA) for its novel Pegvaliase, prescribed for ...
BioMarin Pharmaceutical Inc. BMRN announced that the FDA has placed its phase I/II study — PHEARLESS — evaluating its AAV5-phenylalanine hydroxylase gene therapy candidate, BMN 307, under clinical ...
Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.23 per share a year ago. These ...
As with many other companies Eton Pharmaceuticals, Inc. (NASDAQ:ETON) makes use of debt. But should shareholders be worried about its use of debt? Generally speaking, debt only becomes a real problem ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.